Literature DB >> 22227118

Investigation of the antiviral properties of copper iodide nanoparticles against feline calicivirus.

Nozomi Shionoiri1, Tetsuya Sato, Yoshie Fujimori, Tsuruo Nakayama, Michiko Nemoto, Tadashi Matsunaga, Tsuyoshi Tanaka.   

Abstract

This study demonstrated the antiviral properties of copper iodide (CuI) nanoparticles against the non-enveloped virus feline calicivirus (FCV) as a surrogate for human norovirus. The effect of CuI nanoparticles on FCV infectivity to Crandell-Rees feline kidney (CRFK) cells was elucidated. The infectivity of FCV to CRFK cells was greatly reduced by 7 orders of magnitude at 1000μgml(-1) CuI nanoparticles. At the conditions, electron spin resonance (ESR) analysis proved hydroxyl radical production in CuI nanoparticle suspension. Furthermore, amino acid oxidation in the viral capsid protein of FCV was determined by nanoflow liquid chromatography-mass spectrometric (nano LC-MS) analysis. The use of CuI nanoparticles showed extremely high antiviral activity against FCV. The high antiviral property of CuI nanoparticles was attributed to Cu(+), followed by ROS generation and subsequent capsid protein oxidation. CuI nanoparticles could be proposed as useful sources of a continuous supply of Cu(+) ions for efficient virus inactivation. Furthermore, this study brings new insights into toxic actions of copper iodide nanoparticles against viruses.
Copyright © 2011 The Society for Biotechnology, Japan. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227118     DOI: 10.1016/j.jbiosc.2011.12.006

Source DB:  PubMed          Journal:  J Biosci Bioeng        ISSN: 1347-4421            Impact factor:   2.894


  22 in total

1.  Destruction of the Capsid and Genome of GII.4 Human Norovirus Occurs during Exposure to Metal Alloys Containing Copper.

Authors:  C S Manuel; M D Moore; L A Jaykus
Journal:  Appl Environ Microbiol       Date:  2015-05-15       Impact factor: 4.792

Review 2.  Exploring the Role of Heavy Metals and Their Derivatives on the Pathophysiology of COVID-19.

Authors:  Ali Bahrami; Mohammad Reza Arabestani; Mohammad Taheri; Abbas Farmany; Fatemeh Norozzadeh; Seyed Mostafa Hosseini; Hesam Nozari; Fatemeh Nouri
Journal:  Biol Trace Elem Res       Date:  2021-08-27       Impact factor: 4.081

3.  Ponderomotive forces in the system of two nanoparticles.

Authors:  Valeri Lozovski; Volodymyr Lysenko; Natalia Rusinchuk
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

Review 4.  Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review.

Authors:  V Govind; S Bharadwaj; M R Sai Ganesh; Jithin Vishnu; Karthik V Shankar; Balakrishnan Shankar; R Rajesh
Journal:  Biometals       Date:  2021-08-16       Impact factor: 2.949

5.  Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles.

Authors:  Jessica Jenkins Broglie; Brittny Alston; Chang Yang; Lun Ma; Audrey F Adcock; Wei Chen; Liju Yang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

6.  A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.

Authors:  Yasmin Abo-Zeid; Nasser S M Ismail; Gary R McLean; Nadia M Hamdy
Journal:  Eur J Pharm Sci       Date:  2020-07-12       Impact factor: 4.384

7.  Advances in Antiviral Material Development.

Authors:  Lili Liang; Ashiq Ahamed; Liya Ge; Xiaoxu Fu; Grzegorz Lisak
Journal:  Chempluschem       Date:  2020-08-21       Impact factor: 3.210

8.  Inactivation of norovirus on dry copper alloy surfaces.

Authors:  Sarah L Warnes; C William Keevil
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

9.  Inactivation of caliciviruses.

Authors:  Raymond Nims; Mark Plavsic
Journal:  Pharmaceuticals (Basel)       Date:  2013-03-21

Review 10.  Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.

Authors:  Souvik Ghosh; Yashpal Singh Malik; Nobumichi Kobayashi
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.